title: Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus.
abstract: To evaluate the factors determining the severity of chronic hepatitis B virus infection and the interactions of human immunodeficiency virus and hepatitis delta virus infections, we retrospectively analyzed 260 patients, 146 of whom were followed for a mean of 31.4 +/- 1.8 mo. Human immunodeficiency virus, hepatitis B virus, and hepatitis delta virus status and aminotransferase activities, histological activity index, alcohol consumption and the prevalence of cirrhosis were investigated. The patients included 54 homosexuals, 19 parenteral drug abusers and 187 subjects with other or unidentified risk factors for exposure to hepatitis B virus. Thirty-five patients (13%) were positive for antibody to human immunodeficiency virus; 27 were homosexual and 8 were drug abusers. The mean aminotransferase activities, histological activity index and the prevalence of cirrhosis were similar in the human immunodeficiency virus-positive and human immunodeficiency virus-negative subgroups. Actuarial survival was significantly lower in the human immunodeficiency virus-negative subgroups. Actuarial survival was significantly lower in the human immunodeficiency virus-positive group than in the human immunodeficiency virus-negative subjects (p = 0.004); the cause of death was clearly related to liver failure in four of the five human immunodeficiency virus-positive patients and two of the six human immunodeficiency virus-negative subjects who died. To evaluate the factors determining the severity of liver disease, we compared homogeneous subgroups of subjects. Among the homosexual patients, the prevalence of HBeAg and hepatitis B virus DNA, aminotransferase activities and the histological activity index did not differ according to human immunodeficiency virus antibody status.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Unité d'Hépatologie, Hôpital Laënnec, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Housset
authors.forename: S
authors.initials: S
authors.lastname: Pol
authors.forename: F
authors.initials: F
authors.lastname: Carnot
authors.forename: F
authors.initials: F
authors.lastname: Dubois
authors.forename: B
authors.initials: B
authors.lastname: Nalpas
authors.forename: B
authors.initials: B
authors.lastname: Housset
authors.forename: P
authors.initials: P
authors.lastname: Berthelot
authors.forename: C
authors.initials: C
authors.lastname: Brechot
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D002353:Carrier State / Q000503:physiopathology*; D005260:Female; D005500:Follow-Up Studies; D015483:HIV Antibodies / Q000032:analysis; D015497:HIV-1 / Q000276:immunology; D006508:Hepatitis Antibodies / Q000032:analysis; D006509:Hepatitis B / Q000150:complications* / Q000276:immunology / Q000635:transmission; D003699:Hepatitis D / Q000150:complications* / Q000276:immunology; D006801:Humans; D008297:Male; D012044:Regression Analysis; D012189:Retrospective Studies
chemical_list: D015483:HIV Antibodies; D006508:Hepatitis Antibodies